Role of AGR2 Expression in Specimens from Pituitary Adenoma Tissue on Tumor Behavior

Gremlin is an antagonist of bone morphogenetic protein (BMP) and a major driving force in skeletal modeling in the fetal stage. Several recent reports have shown that Gremlin is also involved in angiogenesis of lung cancer and diabetic retinopathy. The purpose of this study was to investigate the role of Gremlin in tumor angiogenesis in pituitary adenoma. Double fluorescence immunohistochemistry of Gremlin and CD34 was performed in pituitary adenoma tissues obtained during transsphenoidal surgery in 45 cases (7 PRLoma, 17 GHoma, 2 ACTHoma, and 2 TSHoma). Gremlin and microvascular density (MVD) were detected by double-immunofluorescence microscopy in CD34-positive vessels from tissue microarray analysis of 60 cases of pituitary adenomas (6 PRLoma, 23 GHoma, 22 NFoma, 5 ACTHoma, and 4 TSHoma). In tissue microarray analysis, MVD was significantly correlated with an increased Gremlin level (linear regression:P<0.005, r2=0.4958). In contrast, Gremlin expression showed no correlation with tumor subtype or Knosp score. The high level of expression of Gremlin in pituitary adenoma tissue with many CD34-positive vessels and the strong coherence of these regions indicate that Gremlin is associated with angiogenesis in pituitary adenoma cells.

Download Full-text

The Importance of AGR2 Expression in Pituitary Adenoma Tissue Specimens on Tumor Aggressivity

Endocrine Abstracts ◽

10.1530/endoabs.63.p283 ◽

2019 ◽

Author(s):

Sema Ciftci Dogansen ◽

Omur Gunaldi ◽

Ayla Solmaz Avcikurt ◽

Baris Colluoglu ◽

Ilhan Yilmaz ◽

...

Keyword(s):

Pituitary Adenoma ◽

Adenoma Tissue ◽

Tissue Specimens

Download Full-text

PTTG has a Dual Role of Promotion-Inhibition in the Development of Pituitary Adenomas

Protein and Peptide Letters ◽

10.2174/0929866526666190722145449 ◽

2019 ◽

Vol 26 (11) ◽

pp. 800-818

Author(s):

Zujian Xiong ◽

Xuejun Li ◽

Qi Yang

Keyword(s):

Cell Cycle ◽

Pituitary Adenoma ◽

Pituitary Adenomas ◽

Cell Cycle Progression ◽

Key Factors ◽

Cycle Progression ◽

Sister Chromatids ◽

Regulation Of Cell Cycle ◽

Late Stages

Pituitary Tumor Transforming Gene (PTTG) of human is known as a checkpoint gene in the middle and late stages of mitosis, and is also a proto-oncogene that promotes cell cycle progression. In the nucleus, PTTG works as securin in controlling the mid-term segregation of sister chromatids. Overexpression of PTTG, entering the nucleus with the help of PBF in pituitary adenomas, participates in the regulation of cell cycle, interferes with DNA repair, induces genetic instability, transactivates FGF-2 and VEGF and promotes angiogenesis and tumor invasion. Simultaneously, overexpression of PTTG induces tumor cell senescence through the DNA damage pathway, making pituitary adenoma possessing the potential self-limiting ability. To elucidate the mechanism of PTTG in the regulation of pituitary adenomas, we focus on both the positive and negative function of PTTG and find out key factors interacted with PTTG in pituitary adenomas. Furthermore, we discuss other possible mechanisms correlate with PTTG in pituitary adenoma initiation and development and the potential value of PTTG in clinical treatment.

Download Full-text

Role of matrix Metalloproteinases in pituitary adenoma invasion

Chinese Neurosurgical Journal ◽

10.1186/s41016-017-0109-0 ◽

2018 ◽

Vol 4 (1) ◽

Author(s):

Chengxian Yang ◽

Xinjie Bao ◽

Renzhi Wang

Keyword(s):

Pituitary Adenoma ◽

Matrix Metalloproteinases

Download Full-text

The Pathogenic Role of AIP Mutations – The Importance of the Integration of Clinical, Experimental and Modeling Data on Advising Patients and Their Families with Pituitary Adenoma Predisposition.

10.1210/endo-meetings.2010.part2.p2.p2-86 ◽

2010 ◽

pp. P2-86-P2-86

Author(s):

G Trivellin ◽

GB Bolger ◽

S Igreja ◽

H Chahal ◽

AB Grossman ◽

...

Keyword(s):

Pituitary Adenoma ◽

Pathogenic Role ◽

Modeling Data

Download Full-text

26 Atypical Adenoma, Pituitary Carcinoma, and the Role of Chemotherapy in the Management of Refractory Pituitary Adenoma

Endoscopic Pituitary Surgery ◽

10.1055/b-0034-82144 ◽

2012 ◽

Keyword(s):

Pituitary Adenoma ◽

Pituitary Carcinoma ◽

Atypical Adenoma

Download Full-text

MPTH-07. ROLE OF CELL-CYCLE REGULATORS IN PREDICTING PROGRESSION OF SILENT PITUITARY ADENOMA AFTER SURGICAL RESECTION

Neuro-Oncology ◽

10.1093/neuonc/now212.445 ◽

2016 ◽

Vol 18 (suppl_6) ◽

pp. vi106-vi107

Author(s):

Sung Hyun Park ◽

JI Hwan Jang

Keyword(s):

Cell Cycle ◽

Pituitary Adenoma ◽

Surgical Resection ◽

Cell Cycle Regulators ◽

Silent Pituitary Adenoma

Download Full-text

Treatment Complexities of a Young Woman Suffering Psychosis and Pituitary Adenoma

Case Reports in Psychiatry ◽

10.1155/2011/246820 ◽

2011 ◽

Vol 2011 ◽

pp. 1-4

Author(s):

Maxine Sigman ◽

Kate Drury

Keyword(s):

Pituitary Adenoma ◽

Young Woman ◽

Interdisciplinary Team ◽

Psychotic Symptoms ◽

Team Approach ◽

Pharmacological Management ◽

Clinical Description ◽

One Year

This paper is a clinical description of the presentation, therapy, and pharmacological management of a 28-year-old woman who had nine admissions to a psychiatry ward, the last four within one year. It became clear that the treatments, which the patient had received concurrently for ten years for a pituitary adenoma and for psychotic symptoms, were counteractive. The case highlights the importance of the role of prolactin in psychosis and of an interdisciplinary team approach when patients present with complex symptoms.

Download Full-text

The efficacy of dopamine agonist therapy in a young man with a giant prolactinoma: case report

Problems of Endocrinology ◽

10.14341/probl2017634231-235 ◽

2017 ◽

Vol 63 (4) ◽

pp. 231-235

Author(s):

Alexandr I. Tsiberkin ◽

Tatiana L. Karonova ◽

Anna B. Dalmatova ◽

Elena N. Grineva

Keyword(s):

Pituitary Adenoma ◽

Pituitary Adenomas ◽

Young Patients ◽

Young Male ◽

Serum Prolactin ◽

Agonist Therapy ◽

Giant Prolactinoma ◽

Dopamine Agonist Therapy ◽

History Of

Prolactinomas are the most common of hormone secreting pituitary adenomas. Patients with prolactinomas generally have a benign prognosis. An algorithm is currently available for managing of this disease. Giant prolactinoma larger than 40 mm with severe invasive growth account for about 2—3% of the prolactin-secreting pituitary adenomas and evidence about management of such patients is limited. This case illustrates progress of a giant prolactin-secreting pituitary adenoma up to 70 mm in young male with a family history of prolactinomas in the absence of the adequate therapy for 8 years after initial diagnosis. After evaluation, it was decided to prescribe medical treatment. Cabergoline therapy started after evaluation appeared to be effective and had lead to significant decrease of serum prolactin level and shrinkage of pituitary adenoma. Described case emphasize the crucial role of identification of hyperprolactinemia among young patients on early stages of the disease. Our observation implies that treatment with dopamine agonists might be effective even in cases with giant prolactinomas.

Download Full-text